Myocardial Ischemia Market Research Report - Forecast till 2027

Myocardial Ischemia Market: Information by Type (Symptomatic and Asymptomatic), Treatment & Diagnosis (Diagnosis and Treatment), End User (Hospitals & Clinics, Diagnostic Centers and Ambulatory Surgery Centers) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/MED/4355-CR | August 2019 | Region: Global | 135 Pages         

1 Report Prologue

2 Market Introduction

2.1 Introduction 16

2.2 Assumptions & Limitations 16

3 Research Methodology

3.1 Research Process 19

3.2 Primary Research 19

3.3 Secondary Research 20

3.4 Market Size Estimation 20

4 Market Dynamics

4.1 Introduction 22

4.2 Drivers 23

4.2.1 High Prevalence Of Coronary Heart Disease 23

4.2.2 Rising Prevalence Of Diabetes 23

4.2.3 Lifestyle Changes 23

4.2.4 Drivers Impact Analysis 23

4.3 Restraints 24

4.3.1 High Cost Of Therapeutic Surgeries 24

4.3.2 Side Effects Related To Medications 24

4.3.3 Restraints Impact Analysis 24

4.4 Opportunity 25

4.4.1 Untapped Markets Of The Asia-Pacific Region 25

4.5 Macroeconomic Indicator 25

5 Market Factor Analysis

5.1 Value Chain Analysis 27

5.1.1 R&D And Designing 27

5.1.2 Manufacturing 27

5.1.3 Distribution & Sales 27

5.1.4 Post-Sales Review 28

5.2 Porter’s Five Forces Model 28

5.2.1 Bargaining Power Of Suppliers 28

5.2.2 Bargaining Power Of Buyers 29

5.2.3 Threat Of New Entrants 29

5.2.4 Threat Of Substitutes 29

5.2.5 Intensity Of Rivalry 29

5.3 Investment Opportunities 29

5.4 Pricing Analysis 30

5.5 Demand & Supply: Gap Analysis 30

6 Myocardial Ischemia Market, By Type

6.1 Introduction 32

6.2 Symptomatic 33

6.3 Asymptomatic 33

7 Myocardial Ischemia Market, By Treatment & Diagnosis

7.1 Introduction 35

7.2 Diagnosis 37

7.3 Treatment 37

8 Myocardial Ischemia Market:, By End User

8.1 Introduction 39

8.2 Hospitals & Clinics 40

8.3 Diagnostic Centers 40

8.4 Ambulatory Surgery Centers 40

9 Global Myocardial Ischemia Market, By Region

9.1 Introduction 42

9.2 Americas 43

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.2.1 North America 46

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.2.1.1 US. 48

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.2.1.2 Canada 50

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.2.2 South America 52

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3 Europe 55

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.1 Western Europe 58

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.1.1 Germany 60

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.1.2 France 62

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.1.3 UK 64

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.1.4 Italy 66

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.1.5 Spain 68

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.1.6 Rest Of Western Europe 70

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.3.2 Eastern Europe 72

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.4 Asia-Pacific 75

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.4.1 Japan 78

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.4.2 China 80

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.4.3 India 82

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.4.4 Australia 84

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.4.5 Republic Of Korea 86

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.4.6 Rest Of Asia-Pacific 88

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.5 Middle East & Africa 91

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.5.1 United Arab Emirates 94

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.5.2 Saudi Arabia 96

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.5.3 Oman 98

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.5.4 Kuwait 100

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.5.5 Qatar 102

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

9.5.6 Rest Of The Middle East & Africa 105

Myocardial Ischemia Market, By Type

Myocardial Ischemia Market, By Treatment & Diagnosis

Myocardial Ischemia Market:, By End User

10 Competitive Landscape

10.1 Introduction 109

11 Company Profiles

11.1 Taxus Cardium 111

11.1.1 Company Overview 111

11.1.2 Financial Overview 111

11.1.3 Products Offering 111

11.1.4 Key Developments 111

11.1.5 SWOT Analysis 111

11.1.6 Key Strategy 111

11.2 ViroMed Co. Ltd. 112

11.2.1 Company Overview 112

11.2.2 Financial Overview 112

11.2.3 Products Offering 113

11.2.4 Key Developments 113

11.2.5 SWOT Analysis 113

11.2.6 Key Strategy 113

11.3 Edwards Lifesciences Corporation 114

11.3.1 Company Overview 114

11.3.2 Financial Overview 114

11.3.3 Products Offering 115

11.3.4 Key Developments 115

11.3.5 SWOT Analysis 115

11.3.6 Key Strategy 115

11.4 Daiichi Sankyo Company Limited 116

11.4.1 Company Overview 116

11.4.2 Financial Overview 116

11.4.3 Products Offering 117

11.4.4 Key Developments 117

11.4.5 SWOT Analysis 117

11.4.6 Key Strategy 117

11.5 Boston Scientific Corporation 118

11.5.1 Company Overview 118

11.5.2 Financial Overview 118

11.5.3 Products Offering 119

11.5.4 Key Developments 119

11.5.5 SWOT Analysis 119

11.5.6 Key Strategy 119

11.6 Merck KGaA 120

11.6.1 Company Overview 120

11.6.2 Financial Overview 120

11.6.3 Products Offering 121

11.6.4 Key Developments 121

11.6.5 SWOT Analysis 121

11.6.6 Key Strategy 121

11.7 Novartis AG 122

11.7.1 Company Overview 122

11.7.2 Financial Overview 122

11.7.3 Products Offering 123

11.7.4 Key Developments 123

11.7.5 SWOT Analysis 123

11.7.6 Key Strategy 123

11.8 Boehringer Ingelheim International GmbH 124

11.8.1 Company Overview 124

11.8.2 Financial Overview 124

11.8.3 Products Offering 125

11.8.4 Key Developments 125

11.8.5 SWOT Analysis 125

11.8.6 Key Strategy 125

11.9 Johnson & Johnson Services Inc. (Janssen Global Services, LLC) 126

11.9.1 Company Overview 126

11.9.2 Financial Overview 126

11.9.3 Products Offering 127

11.9.4 Key Developments 127

11.9.5 SWOT Analysis 127

11.9.6 Key Strategy 127

11.10 Bayer AG 128

11.10.1 Company Overview 128

11.10.2 Financial Overview 128

11.10.3 Products Offering 129

11.10.4 Key Developments 129

11.10.5 SWOT Analysis 129

11.10.6 Key Strategy 129

11.11 AstraZeneca 130

11.11.1 Company Overview 130

11.11.2 Financial Overview 130

11.11.3 Products Offering 131

11.11.4 Key Developments 131

11.11.5 SWOT Analysis 131

11.11.6 Key Strategy 131

11.12 Pfizer Inc. 132

11.12.1 Company Overview 132

11.12.2 Financial Overview 132

11.12.3 Products Offering 133

11.12.4 Key Developments 133

11.12.5 SWOT Analysis 133

11.12.6 Key Strategy 133

12 Appendix

12.1 Discussion Blue Print 135

13 List Of Tables

TABLE 1 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 32

TABLE 2 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR SYMPTOMATIC TYPE 2020-2027 (USD MILLION) 33

TABLE 3 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR ASYMPTOMATIC TYPE 2020-2027 (USD MILLION) 33

TABLE 4 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 35

TABLE 5 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 36

TABLE 6 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 36

TABLE 7 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR DIAGNOSIS, BY REGION 2020-2027 (USD MILLION) 37

TABLE 8 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR TREATMENT, BY REGION 2020-2027 (USD MILLION) 37

TABLE 9 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 39

TABLE 10 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR HOSPITALS & CLINICS 2020-2027 (USD MILLION) 40

TABLE 11 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR DIAGNOSTIC CENTERS 2020-2027 (USD MILLION) 40

TABLE 12 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR AMBULATORY SURGERY CENTERS 2020-2027 (USD MILLION) 40

TABLE 13 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 42

TABLE 14 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 43

TABLE 15 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 43

TABLE 16 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 44

TABLE 17 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 44

TABLE 18 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 44

TABLE 19 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 45

TABLE 23 NORTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 47

TABLE 25 US MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 48

TABLE 26 US MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 48

TABLE 27 US MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 49

TABLE 28 US MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 49

TABLE 29 US MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 50

TABLE 30 CANADA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 50

TABLE 31 CANADA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 50

TABLE 32 CANADA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 51

TABLE 33 CANADA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 51

TABLE 34 CANADA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 52

TABLE 35 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 52

TABLE 36 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 52

TABLE 37 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 53

TABLE 38 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 53

TABLE 39 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 54

TABLE 40 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: REGION 2020-2027 (USD MILLION) 55

TABLE 41 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: TYPE 2020-2027 (USD MILLION) 55

TABLE 42 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 56

TABLE 43 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: DIAGNOSIS TYPE 2020-2027 (USD MILLION) 56

TABLE 44 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: TREATMENT TYPE 2020-2027 (USD MILLION) 56

TABLE 45 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: END USER 2020-2027 (USD MILLION) 57

TABLE 46 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 58

TABLE 47 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 58

TABLE 48 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 58

TABLE 49 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 59

TABLE 50 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 60

TABLE 51 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 60

TABLE 52 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 60

TABLE 53 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 61

TABLE 54 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 61

TABLE 55 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 62

TABLE 56 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 62

TABLE 57 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 62

TABLE 58 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 63

TABLE 59 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 63

TABLE 60 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 64

TABLE 61 UK MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 64

TABLE 62 UK MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 64

TABLE 63 UK MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 65

TABLE 64 UK MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 65

TABLE 65 UK MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 66

TABLE 66 ITALY MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 66

TABLE 67 ITALY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 66

TABLE 68 ITALY MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 67

TABLE 69 ITALY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 67

TABLE 70 ITALY MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 68

TABLE 71 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 68

TABLE 72 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 68

TABLE 73 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 69

TABLE 74 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 69

TABLE 75 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 70

TABLE 76 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 70

TABLE 77 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 70

TABLE 78 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 71

TABLE 79 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 71

TABLE 80 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 72

TABLE 81 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 72

TABLE 82 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 72

TABLE 83 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 73

TABLE 84 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 73

TABLE 85 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 74

TABLE 86 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 75

TABLE 87 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 75

TABLE 88 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 76

TABLE 89 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 76

TABLE 90 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 76

TABLE 91 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 77

TABLE 92 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 78

TABLE 93 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 78

TABLE 94 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 78

TABLE 95 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 79

TABLE 96 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 80

TABLE 97 CHINA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 80

TABLE 98 CHINA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 80

TABLE 99 CHINA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 81

TABLE 100 CHINA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 81

TABLE 101 CHINA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 82

TABLE 102 INDIA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 82

TABLE 103 INDIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 82

TABLE 104 INDIA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 83

TABLE 105 INDIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 83

TABLE 106 INDIA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 84

TABLE 107 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 84

TABLE 108 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 84

TABLE 109 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 85

TABLE 110 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 85

TABLE 111 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 86

TABLE 112 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 86

TABLE 113 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 86

TABLE 114 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 87

TABLE 115 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 87

TABLE 116 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 88

TABLE 117 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 88

TABLE 118 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 88

TABLE 119 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 89

TABLE 120 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 89

TABLE 121 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 90

TABLE 122 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 91

TABLE 123 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 91

TABLE 124 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 92

TABLE 125 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 92

TABLE 126 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 92

TABLE 127 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 93

TABLE 128 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 94

TABLE 129 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET:BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 94

TABLE 130 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 94

TABLE 131 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 95

TABLE 132 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 96

TABLE 133 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 96

TABLE 134 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 96

TABLE 135 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 97

TABLE 136 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 97

TABLE 137 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 98

TABLE 138 OMAN MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 98

TABLE 139 OMAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 98

TABLE 140 OMAN MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 99

TABLE 141 OMAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 99

TABLE 142 OMAN MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 100

TABLE 143 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 100

TABLE 144 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 100

TABLE 145 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 101

TABLE 146 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 101

TABLE 147 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 102

TABLE 148 QATAR MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 102

TABLE 149 QATAR MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 102

TABLE 150 QATAR MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 103

TABLE 151 QATAR MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 103

TABLE 152 QATAR MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 104

TABLE 153 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 105

TABLE 154 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS

2020-2027 (USD MILLION) 105

TABLE 155 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 105

TABLE 156 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 106

TABLE 157 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 107

14 List Of Figures

FIGURE 1 MARKET STRUCTURE 17

FIGURE 2 RESEARCH PROCESS 19

FIGURE 3 DROC ANALYSIS OF GLOBAL MYOCARDIAL ISCHEMIA MARKET: 22

FIGURE 4 DRIVERS IMPACT ANALYSIS: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 23

FIGURE 5 RESTRAINTS IMPACT ANALYSIS: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 24

FIGURE 6 VALUE CHAIN: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 27

FIGURE 7 PORTER’S FIVE FORCES MODEL: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 28

FIGURE 8 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020 & 2027 (USD MILLION) 32

FIGURE 9 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020 & 2027 (USD MILLION) 35

FIGURE 10 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020 & 2027 (USD MILLION) 39

FIGURE 11 GLOBAL MYOCARDIAL ISCHEMIA MARKET: SHARE BY REGION 2020 (%) 42

FIGURE 12 AMERICAS MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 43

FIGURE 13 EUROPE MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 55

FIGURE 14 ASIA PACIFIC MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 75

FIGURE 15 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 91

FIGURE 16 GLOBAL MYOCARDIAL ISCHEMIA MARKET: SHARE ANALYSIS 2020 (%) 109

Myocardial Ischemia Market Speak to Analyst Request a Free Sample

Myocardial Ischemia Market Overview


The Myocardial Ischemia Market is expected to register a CAGR of 6.00% and is anticipated to reach USD 50,120.3 Million by 2023. Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.


Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.


Market Dynamics


Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased. This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.


Myocardial Ischemia Market Size, by End User, 2017 (USD Million)  Myocardial Ischemia Market


 Source: MRFR Analysis


Segmentation


The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic. Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test. The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.


Key Players


The prominent players in the myocardial ischemia market are Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).


Some of the key strategies followed by the players operating in the myocardial ischemia market were innovation, product development, acquisition, and expansion.


Asia-Pacific Myocardial Ischemia Market Share, by Country, 2017 (%)
 Myocardial Ischemia Market


Source: MRFR Analysis


Regional Analysis


The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the myocardial ischemia market during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population. The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).


Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.


Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.


Key Updates



  • In July 2016, Angionetics Inc., a subsidiary of Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a USD 3,000,000 investment, to support the Generx Phase 3 clinical and commercialization development program.



  • In February 2018Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.



  • In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).


Market Segmentation


Myocardial Ischemia Market, by Type



  • Symptomatic

  • Asymptomatic


Myocardial Ischemia Market, by Treatment & Diagnosis



  • Diagnosis

  • Treatment


Myocardial Ischemia Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centres

  • Ambulatory Surgery Centres


Myocardial Ischemia Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • United Arab Emirates

    • Saudi Arabia

    • Oman

    • Kuwait

    • Qatar

    • Rest of The Middle East & Africa




Available Additional Customizations



  • Regulatory scenario


Intended Audience



  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Pharmaceutical companies



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 50,120.3 Million
  • 2027: Significant Value
  •   CAGR   6.00% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Treatment & Diagnosis, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rising prevalence of diabetes
  • The increasing cases of coronary artery disease and diabetes
  • Growing awareness related to heart conditions
  • Technological advancement in treatments
  • Rising numbers of hospitals and healthcare infrastructure


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Myocardial ischemia market projected to grow at approximately 6.00% CAGR during the assessment period (2020-2027).

    The valuation of the myocardial ischemia market is estimated to increase to USD 50,120.3 MN by the end of 2023.

    Increasing awareness about heart conditions, technological advancement in medical science, and rising numbers of hospitals & healthcare infrastructure, are major tailwinds pushing the growth of the global myocardial ischemia market.

    North America holds the largest share in the myocardial ischemia market, followed by Europe and the Asia Pacific, respectively.

    ViroMed Co. Ltd. (Korea), Johnson & Johnson Services Inc. (US), Boehringer Ingelheim International GmbH (Germany), Taxus Cardium (US), Bayer AG (Germany), Daiichi Sankyo Company Limited (Japan), AstraZeneca (UK), Edward Lifesciences (US), Boston Scientific Corporation (US), Novartis AG (Switzerland), and Merck KGaA (Germany), are some of the top players operating in the myocardial ischemia market.

    Myocardial Ischemia Market: Competitive Landscape


    Numerous players are operating in this market all over the globe. Many organizations especially in the American, European, and Asian regions have their manufacturing units, while some organizations outsource their facility of manufacturing to other organizations. As there are plenty of large and small market players available, it is  very tricky to analyze their market shares.


    The global market for myocardial ischemia is majorly dominated by companies including Boston Scientific, Inc., Edward Lifesciences, Johnson and Johnson Services Inc. (Janssen Global Services, LLC.), and Pfizer Inc. which accounts for ~19.3% of the market.


    Boston Scientific Inc. is the leader in the myocardial ischemia market and is estimated to hold approximately, 8.10% of the total market. Boston Scientific, Inc has a vast product portfolio in the myocardial ischemia industry. The company also has a wide geographic presence as it operates in various countries across the world. It has a significant presence in North America, Europe, and the Middle East and Africa, with commercial, manufacturing, and research facilities in more than one dozen countries. The company is focusing on expanding the category leadership and driving the growth globally. It is also advancing in patient care and delivering strong financial performance.


    In June 2017, Edward Lifesciences followed the leadership of Boston Scientific Inc. and stood second. The company held 5.20% of the total market share. The company pioneers in the science of heart valves and hemodynamic monitoring. The company partners with medical practitioners to develop new technologies for the treatment of structural heart disease and critical care monitoring. It is advancing its innovations to develop efficient products to transform the patient care. For instance, in February 2018, Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.


    Johnson & Johnson Services Inc. (Janssen Global Services, LLC) stood third in the global myocardial ischemia market in 2017 with a share of 3.80%. The company is aimed at creating a world without disease by transforming lives through new and better ways to prevent, intercept, treat, and cure diseases. The company focuses on increasing investments in R&D to produce more innovative products. As a result, in June 2018, the Janssen Pharmaceutical Companies of Johnson & Johnson announced new findings from two real-world studies comparing sodium glucose co-transporter-2 inhibitor (SGLT2i) INVOKANA (canagliflozin) and glucagon-like peptide-1 receptor agonists (GLP-1s) in treating adults with type 2 diabetes.


    Apart from these major players, there are many small scaled companies which operate in the myocardial ischemia market. These companies manufacture various types of medical devices and robotic products and majorly operate in specific regions and countries. Some of these companies include Taxus Cardium and ViroMed Co. Ltd., among others.


    New product launches, product approvals, and product enhancements are the primary growth strategies adopted by major players to enhance their positions in the global market for myocardial ischemia.


    Moreover, strategies such as partnerships, agreements, and collaborations, geographic expansions,  and acquisitions were also adopted by a significant number of market players to strengthen their product portfolios and expand their geographic presence in the market.